The European Hematology Association (EHA)

Research

Secondary leukemogenesis in the context of T-cell based immunotherapies project

An SWG Grant-supported project initiated by the EHA SWG on Immune Therapies for Hematologic Disorders.

Project lead

Johannes Waldschmidt Johannes Waldschmidt

Department of Internal Medicine II University Medical Center Würzburg Würzburg, Germany
Germany

Project background and aims

Secondary leukemias represent a critical safety concern for T-cell-based immunotherapies in hematologic cancers.

This EHA/SWG-funded project will explore the potential link between T-cell therapy-induced inflammation and the acceleration of pre-existing clonal hematopoiesis of indeterminate potential (CHIP) within the hematopoietic niche.

We will examine the landscape of CHIP mutations in patients with multiple myeloma and B-cell lymphomas (aim 1) and will track CHIP clonal expansion over time during CAR T and bispecific antibody treatment (aim 2).

Funding through the EHA-SWG network offers a unique and invaluable opportunity to expand this study across a vast network of academic centers within the European hematology community.